C. Fumagalli, “In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay”, Pathologica, vol. 114, no. 4, pp. 288-294, Sep. 2022.